Overview
To explore the impact of radiotherapy on peripheral blood myeloid-derived suppressor cells (MDSCs), T cells and extramedullary erythroid precursor cells in patients with malignant tumors, and to evaluate the correlation between changes in the proportion of these cells before and after radiotherapy and the efficacy of radiotherapy in patients.
Description
To clarify the impact of radiotherapy (and/or other treatment combinations) on the proportion of myeloid-derived suppressor cells (MDSCs), T cells and extramedullary erythroid precursor cells in the peripheral blood of patients with malignant tumors, and to evaluate the changes in the proportion of these cells before and after radiotherapy and the relationship between the patients Correlation with the efficacy of radiotherapy. On this basis, it provides theoretical guidance for the determination of new clinical treatment plans.
Eligibility
Inclusion Criteria:
- Over 18 years old, diagnosed with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, head and neck cancer and requiring radiotherapy, and the above malignant tumors have not metastasized.
- Complete inspection information.
- No other serious complications.
- No infectious diseases.
- Able and willing to take blood tests.
- All researchers gave informed consent and signed an informed consent form, which complied with the requirements of the Medical Ethics Committee.
Exclusion Criteria:
- People with mental illness.
- People with autoimmune system diseases.
- Those combined with serious diseases of other organs.
- Those with severe alcoholism and drug abuse.
- Research subjects who voluntarily withdraw from the study.